Trial · NCT02100228
Adverse events294
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 294
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ATRIAL FIBRILLATION | Cardiac disorders | Apixaban | 43 | 735 | |
| other | ATRIAL FIBRILLATION | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 46 | 721 | |
| other | ATRIAL THROMBOSIS | Cardiac disorders | Apixaban | 17 | 735 | |
| other | ATRIAL THROMBOSIS | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 13 | 721 | |
| other | INTERNATIONAL NORMALISED RATIO ABNORMAL | Investigations | Apixaban | 0 | 735 | |
| other | INTERNATIONAL NORMALISED RATIO ABNORMAL | Investigations | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 19 | 721 | |
| other | INTERNATIONAL NORMALISED RATIO INCREASED | Investigations | Apixaban | 0 | 735 | |
| other | INTERNATIONAL NORMALISED RATIO INCREASED | Investigations | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 27 | 721 | |
| other | DYSPNOEA | Respiratory, thoracic and mediastinal disorders | Apixaban | 15 | 735 | |
| other | DYSPNOEA | Respiratory, thoracic and mediastinal disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 8 | 721 | |
| serious | HAEMORRHAGIC ANAEMIA | Blood and lymphatic system disorders | Apixaban | 1 | 735 | |
| serious | HAEMORRHAGIC ANAEMIA | Blood and lymphatic system disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 0 | 721 | |
| serious | ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | Apixaban | 2 | 735 | |
| serious | ACUTE MYOCARDIAL INFARCTION | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 0 | 721 | |
| serious | ANGINA PECTORIS | Cardiac disorders | Apixaban | 2 | 735 | |
| serious | ANGINA PECTORIS | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 0 | 721 | |
| serious | ARTERIOSCLEROSIS CORONARY ARTERY | Cardiac disorders | Apixaban | 1 | 735 | |
| serious | ARTERIOSCLEROSIS CORONARY ARTERY | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 0 | 721 | |
| serious | ATRIAL FIBRILLATION | Cardiac disorders | Apixaban | 27 | 735 | |
| serious | ATRIAL FIBRILLATION | Cardiac disorders | Parenteral Heparin/Oral Vitamin K Antagonist (Usual Care) | 40 | 721 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02100228/events